Bacterial Conjunctivitis
📧 Sign up to get email alerts when something new happens for Bacterial Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis [Phase 3]
Phase 3 clinical trial evaluating fusidic acid 1% for bacterial conjunctivitis is currently recruiting.
-
FDA approval · 2025-12-10FDA Approved: LOTEPREDNOL ETABONATE AND TOBRAMYCIN — Original Application (Alembic Pharmaceuticals Inc.)
FDA approves Alembic Pharmaceuticals' original ANDA for Loteprednol etabonate and tobramycin ophthalmic suspension, a combination eye drop f…
-
CLINICAL_TRIALS trial_result · 2025-07-10Clinical Trial Update: Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine [Phase 4]
Phase 4 trial comparing topical hypochlorous acid (Avenova) to povidone-iodine (Betadine) for bacterial eye infections is currently suspende…
-
FDA approval · 2025-07-01FDA Approved: NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for Neomycin and Polymyxin B Sulfates and Hydrocortisone (neomycin sulfate, polymyxin B sulfate, hyd…
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis [Phase 2]
Phase 2 trial results evaluating IVIEW-1201 for acute bacterial conjunctivitis have been reported, detailing the treatment's efficacy and sa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects [Phase 1]
A Phase 1 trial comparing the safety and tolerability of PRO-231 versus VIGAMOXI on the ocular surface in healthy subjects has completed, wi…
-
FDA approval · 2025-04-07FDA Approved: TOBRAMYCIN AND DEXAMETHASONE — Supplemental Application (Sandoz Inc)
Supplemental FDA approval for tobramycin and dexamethasone (Sandoz) as an ophthalmic combination product.
-
FDA approval · 2025-01-27FDA Approved: MOXIFLOXACIN OPHTHALMIC SOLUTION — Original Application (Lifestar Pharma LLC)
FDA approved a generic ophthalmic moxifloxacin solution from Lifestar Pharma LLC under an original ANDA for the treatment of bacterial conju…
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis [Phase 3]
Phase 3 trial evaluating the safety and efficacy of vancomycin ophthalmic ointment for moderate to severe bacterial conjunctivitis; results …
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults [Phase 2]
Phase 2 clinical trial evaluating RD03/2016 for the treatment of bacterial conjunctivitis in adults has completed, assessing its effects and…
-
FDA approval · 2024-04-12FDA Approved: OFLOXACIN — Original Application (Leading Pharma, LLC)
FDA approved the original application for OFLOXACIN ophthalmic solution 0.3% from Leading Pharma, LLC.
-
FDA approval · 2023-07-27FDA Approved: TOBRAMYCIN — Original Application (Micro Labs Limited)
FDA approved Tobramycin ophthalmic solution from Micro Labs Limited under an Original Application.
-
FDA approval · 2023-07-21FDA Approved: TOBRAMYCIN AND DEXAMETHASONE — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for Tobramycin and Dexamethasone (Bausch & Lomb Incorporated), authorizing changes to the product's …
-
FDA approval · 2023-06-09FDA Approved: CIPROFLOXACIN AND DEXAMETHASONE — Original Application (ARMAS PHARMACEUTICALS INC.)
FDA approved an original ANDA for ciprofloxacin and dexamethasone from Armas Pharmaceuticals Inc., a generic antibiotic-steroid combination …
-
FDA approval · 2022-02-11FDA Approved: TOBRAMYCIN AND DEXAMETHASONE — Original Application (Padagis US LLC)
The FDA approved Padagis US LLC's generic Tobramycin and Dexamethasone ophthalmic suspension as an original ANDA for treatment of inflammati…
-
FDA approval · 2021-11-03FDA Approved: GATIFLOXACIN — Original Application (Leading Pharma, LLC)
FDA approved gatifloxacin ophthalmic solution 0.5% under an original ANDA from Leading Pharma, LLC for use in treating bacterial conjunctivi…
-
FDA approval · 2021-10-25FDA Approved: LOTEPREDNOL ETABONATE AND TOBRAMYCIN — Supplemental Application (Bausch & Lomb Americas Inc.)
FDA approved a supplemental application for the Loteprednol etabonate and tobramycin ophthalmic product from Bausch & Lomb Americas Inc.
-
CLINICAL_TRIALS trial_result · 2021-08-24Clinical Trial Update: Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. [Phase 3]
Phase 3 trial evaluating efficacy of ophthalmic pazufloxacin 0.6% vs gatifloxacin 0.3% for bacterial conjunctivitis; study terminated with p…
-
FDA approval · 2021-07-19FDA Approved: MOXIFLOXACIN OPHTHALMIC SOLUTION — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's supplemental application for moxifloxacin ophthalmic solution. This approval concerns the gen…
-
FDA approval · 2021-05-14FDA Approved: NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND DEXAMETHASONE — Supplemental Application (Nordic Pharma, Inc.)
FDA approved a supplemental application for NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND DEXAMETHASONE from Nordic Pharma, Inc., updating its a…
-
FDA approval · 2021-05-14FDA Approved: MAXITROL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for MAXITROL (neomycin sulfate, polymyxin B sulfate and dexamethasone), updating labeling for this o…
-
FDA approval · 2021-05-14FDA Approved: TOBREX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TOBREX (tobramycin) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2020-06-02FDA Approved: VIGAMOX — Supplemental Application (Harrow Eye, LLC)
FDA approved a supplemental application for VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) from Harrow Eye, LLC.
-
FDA approval · 2020-05-11FDA Approved: VIGAMOX — Supplemental Application (Harrow Eye, LLC)
FDA approved a supplemental application for VIGAMOX (moxifloxacin hydrochloride) filed by Harrow Eye, LLC. This represents a supplemental ap…
-
FDA approval · 2020-04-24FDA Approved: TOBRADEX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TOBRADEX (tobramycin and dexamethasone) to update the ophthalmic label for inflammatory and infe…